Key Highlights

Risk & Performance

Based on historical performance

High Risk

Score: 80/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Phase 3

2(66.7%)

N/A

1(33.3%)

3Total

Phase 3(2)

N/A(1)

Loading network data...

Showing 5 of 5 trials

EXtended Use of FOsfomycin for the Treatment of CYstitis in Primary Care

Role: lead

Study to Collect Information About Invasive Disease Caused by Extraintestinal Pathogenic Escherichia Coli (EXPECT-1)

Role: lead

AssessmeNT of the Incidence of Clostridium Difficile Infections in Hospitalized Patients on Antibiotic TrEatment

Role: lead

DiagNostic Study of Low-dose CT and multipleX PCR on Antibiotic Treatment and Outcome of Community-Acquired Pneumonia

Role: lead

Ecological Effects of Decolonisation Strategies in Intensive Care

Role: lead

All 5 trials loaded